Susquehanna International Group, LLP Immunome Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Immunome Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 51,631 shares of IMNM stock, worth $566,392. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,631

Previous 29,711 73.78%

Holding current value

$566,392

Previous $359,000 110.03%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$11.7 - $16.51 $256,463 - $361,899	21,920 Added 73.78%	51,631 $754,000
Q2 2024 Aug 15, 2024	SELL	$11.54 - $22.11 $3.34 Million - $6.41 Million	-289,803 Reduced 90.7%	29,711 $359,000
Q1 2024 May 07, 2024	BUY	$11.01 - $27.34 $3.13 Million - $7.78 Million	284,687 Added 817.43%	319,514 $7.89 Million
Q4 2023 Feb 14, 2024	BUY	$7.3 - $10.73 $70,795 - $104,059	9,698 Added 38.59%	34,827 $372,000
Q3 2023 Nov 14, 2023	BUY	$6.17 - $9.16 $47,293 - $70,211	7,665 Added 43.89%	25,129 $209,000
Q2 2023 Aug 11, 2023	BUY	$4.7 - $7.91 $23,091 - $38,861	4,913 Added 39.14%	17,464 $138,000
Q1 2023 May 16, 2023	SELL	$3.26 - $5.69 $31,012 - $54,128	-9,513 Reduced 43.12%	12,551 $62,000
Q4 2022 Feb 14, 2023	BUY	$2.21 - $5.0 $48,761 - $110,320	22,064 New	22,064 $48,000
Q2 2022 Aug 15, 2022	SELL	$2.24 - $5.79 $48,641 - $125,729	-21,715 Reduced 64.31%	12,052 $39,000
Q1 2022 May 16, 2022	SELL	$3.88 - $13.99 $122,926 - $443,231	-31,682 Reduced 48.41%	33,767 $192,000
Q4 2021 Feb 14, 2022	BUY	$12.96 - $23.44 $85,121 - $153,953	6,568 Added 11.15%	65,449 $848,000
Q3 2021 Nov 15, 2021	BUY	$12.5 - $27.76 $736,012 - $1.63 Million	58,881 New	58,881 $1.43 Million

Others Institutions Holding IMNM

# of Institutions

121

Shares Held

47.1M

Call Options Held

322K

Put Options Held

1.91M

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $133M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Immunome Inc. Transaction History